Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Exact Sciences Corp Stock Research

EXAS

66.85USD-2.68(-3.85%)Market Closed
Watchlist

Market Summary

USD66.85-2.68
Market Closed
-3.85%

EXAS Alerts

  • 2 major insider sales recently.
  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

EXAS Stock Price

EXAS RSI Chart

EXAS Valuation

Market Cap

12.1B

Price/Earnings (Trailing)

-27.96

Price/Sales (Trailing)

5.25

EV/EBITDA

-37.77

Price/Free Cashflow

-111.47

EXAS Price/Sales (Trailing)

EXAS Profitability

Operating Margin

72.89%

EBT Margin

-23.73%

Return on Equity

-16.9%

Return on Assets

-8.2%

Free Cashflow Yield

-0.9%

EXAS Fundamentals

EXAS Revenue

Revenue (TTM)

2.3B

Revenue Y/Y

19.26%

Revenue Q/Q

3.26%

EXAS Earnings

Earnings (TTM)

-431.7M

Earnings Y/Y

51.21%

Earnings Q/Q

-9.27%

Price Action

52 Week Range

29.27100.77
(Low)(High)

Last 7 days

-12.8%

Last 30 days

-21.0%

Last 90 days

-27.8%

Trailing 12 Months

94.6%

EXAS Financial Health

Current Ratio

2.97

EXAS Investor Care

Shares Dilution (1Y)

2.37%

Diluted EPS (TTM)

-2.43

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for EXAS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-01
Condella Sarah
gifted
-
-
-2,391
evp, human resources
2023-09-01
Condella Sarah
sold
-379,620
84.36
-4,500
evp, human resources
2023-08-21
Elliott Jeffrey Thomas
sold
-2,505,010
82.92
-30,210
chief financial officer
2023-08-07
Baranick Brian
sold
-114,804
85.04
-1,350
gen. mgr., precision oncology
2023-08-04
Baranick Brian
acquired
-
-
2,712
gen. mgr., precision oncology
2023-07-27
Doyle James Edward
sold
-194,840
97.42
-2,000
-
2023-07-19
Herriott James
sold
-130,000
100
-1,300
general counsel
2023-06-09
Doyle James Edward
sold
-126,895
90.51
-1,402
-
2023-06-09
Zanotti Katherine S
sold
-273,974
90.51
-3,027
-
2023-06-08
Sebelius Kathleen
acquired
-
-
3,599
-

1–10 of 50

Which funds bought or sold EXAS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-21
Jefferies Group LLC
new
-
454,860
454,860
-%
2023-09-20
BARCLAYS PLC
reduced
-9.07
3,534,000
17,170,000
0.01%
2023-09-12
Farther Finance Advisors, LLC
added
58.18
35,518
65,354
0.01%
2023-09-07
ST GERMAIN D J CO INC
new
-
46,481
46,481
-%
2023-08-30
Strait & Sound Wealth Management LLC
added
0.08
503,995
1,810,020
1.79%
2023-08-29
EFG Asset Management (Americas) Corp.
reduced
-6.23
65,888
286,677
0.07%
2023-08-24
Arlington Capital Management, Inc.
added
57.62
957,667
1,767,390
1.53%
2023-08-24
Alberta Investment Management Corp
unchanged
-
114,796
413,160
-%
2023-08-22
COMERICA BANK
new
-
-
-
-%
2023-08-22
COMERICA BANK
new
-
57,000
57,000
0.01%

1–10 of 35

Latest Funds Activity

Are funds buying EXAS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own EXAS
No. of Funds

Schedule 13G FIlings of Exact Sciences

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 10, 2023
ark investment management llc
9.03%
16,040,490
SC 13G/A
Feb 09, 2023
vanguard group inc
9.71%
17,252,465
SC 13G/A
Feb 07, 2023
blackrock inc.
6.4%
11,354,134
SC 13G/A
Feb 06, 2023
wellington management group llp
5.86%
10,404,476
SC 13G/A
Sep 12, 2022
price t rowe associates inc /md/
3.7%
6,464,337
SC 13G/A
Mar 10, 2022
price t rowe associates inc /md/
10.7%
18,724,736
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
8.0%
13,788,133
SC 13G/A
Feb 11, 2022
capital world investors
2.7%
4,682,850
SC 13G/A
Feb 09, 2022
ark investment management llc
7.83%
13,496,014
SC 13G
Feb 04, 2022
blackrock inc.
5.5%
9,497,012
SC 13G

Recent SEC filings of Exact Sciences

View All Filings
Date Filed Form Type Document
Sep 06, 2023
4
Insider Trading
Sep 01, 2023
144
Notice of Insider Sale Intent
Aug 23, 2023
4
Insider Trading
Aug 21, 2023
144
Notice of Insider Sale Intent
Aug 08, 2023
4
Insider Trading
Aug 07, 2023
144
Notice of Insider Sale Intent
Aug 01, 2023
S-8
Employee Benefits Plan
Aug 01, 2023
8-K
Current Report
Aug 01, 2023
10-Q
Quarterly Report
Jul 28, 2023
4
Insider Trading

Peers (Alternatives to Exact Sciences)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
93.5B
27.4B
-2.63% 19.73%
17.06
3.42
-0.48% 32.56%
38.1B
10.7B
-13.40% -19.57%
31.56
3.58
-53.67% -91.41%
13.0B
3.5B
-10.13% -13.81%
35.41
3.69
5.81% -61.22%
12.1B
2.3B
-20.97% 94.61%
-27.96
5.25
18.69% 41.23%
MID-CAP
6.9B
1.7B
-1.24% 29.63%
41.88
4.01
10.25% -39.75%
4.4B
5.4B
0.61% -11.20%
62.22
0.82
0.01% -74.39%
3.0B
-
-2.68% -18.72%
-23.7
37.44
122.90% 54.78%
2.9B
256.2M
-4.82% -13.52%
-16.11
11.39
2.51% -17.66%
SMALL-CAP
672.4M
1.6B
-20.87% -68.23%
-1.15
0.42
23.74% 60.24%
560.8M
-
-14.09% -26.23%
-10.86
6.7K
- -13.75%
357.7M
22.1M
-16.67% -40.68%
16.15
16.18
43.14% 124.16%
170.9M
66.2M
-71.28% -88.95%
-0.25
2.73
20.37% -7.56%
14.9M
-
-20.01% -20.99%
-2.2
-
- 19.06%
6.8M
559.4K
-28.74% -92.61%
-0.36
12.16
- 69.86%

Exact Sciences News

MarketBeat
Patten & Patten Inc. TN Has $1.89 Million Stock Position in Exact ....
MarketBeat,
39 hours ago
Zacks Investment Research

Returns for EXAS

Cumulative Returns on EXAS

18.5%


10-Year Cumulative Returns

18.7%


7-Year Cumulative Returns

-2.6%


5-Year Cumulative Returns

-2.9%


3-Year Cumulative Returns

Risks for EXAS

What is the probability of a big loss on EXAS?

100%


Probability that Exact Sciences stock will be more than 20% underwater in next one year

76.2%


Probability that Exact Sciences stock will be more than 30% underwater in next one year.

55%


Probability that Exact Sciences stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does EXAS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Exact Sciences was unfortunately bought at previous high price.

Drawdowns

Financials for Exact Sciences

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue4.6%2,300,611,0002,200,158,0002,084,279,0002,005,096,0001,938,402,0001,851,581,0001,767,087,0001,759,614,0001,711,598,0001,545,647,0001,491,391,0001,320,627,0001,131,069,0001,062,071,000876,293,000723,699,000623,185,000526,209,000454,462,000398,887,000353,170,000
Cost Of Revenue2.1%608,946,000596,555,000574,394,000546,300,000514,101,000483,469,000458,757,000439,464,000418,787,000382,711,000354,324,000324,975,000282,249,000255,496,000216,717,000184,128,000161,478,000136,892,000116,644,000102,312,00093,356,000
Gross Profit----------------537,965,000460,190,000387,889,000336,480,000295,570,000259,144,000
Operating Expenses----------------724,955,000652,445,000579,026,000495,951,000428,714,000379,774,000
  S&GA Expenses-4.9%761,362,000800,794,000846,011,000920,104,000929,024,000907,929,000861,889,000744,412,000684,276,000608,311,000589,919,000542,943,000492,658,000461,986,000385,176,000342,098,000320,738,000286,979,000249,448,000213,302,000186,234,000
  R&D Expenses-0.5%384,601,000386,589,000393,418,000387,586,000372,129,000372,281,000385,600,000743,557,000699,672,000626,110,000554,052,000150,876,000154,119,000151,418,000139,694,000117,171,00099,857,00084,366,00067,285,00059,260,00053,585,000
EBITDA100.0%--390,806,333--611,176,333-633,140,333-644,919,000-738,600,000-821,280,000-896,580,000-790,197,666-689,995,333-542,297,333-381,703,666-374,505,666-301,450,000-246,018,000-----
EBITDA Margin100.0%--0.18--0.30-0.44-0.35-0.42-0.47-0.52-0.51-0.46-0.41-0.34-0.35-0.34-0.34-----
Interest Expenses-11.7%24,912,00028,219,00019,634,00018,330,00018,885,00018,744,00018,606,000117,375,000117,577,000117,929,00067,941,000-77,070,000-85,801,000-94,213,000-61,599,000-58,883,000-56,378,000-52,269,000-36,789,000-25,868,000-15,215,000
Earnings Before Taxes16.8%-434,217,000-522,112,000-632,570,000-727,497,000-746,416,000-751,489,000-842,506,000-1,036,148,000-1,070,642,000-966,152,000-829,063,000-517,250,000-351,802,000-322,350,000-268,879,000-216,163,000-221,658,000-219,101,000-175,057,000-142,810,000-124,601,000
EBT Margin100.0%--0.24-0.30-0.36-0.52-0.41-0.48-0.58-0.63-0.64-0.56-0.41-0.31-0.30-0.31------
Net Income16.5%-431,683,000-516,720,000-623,506,000-716,372,000-734,549,000-745,398,000-595,625,000-793,346,000-828,946,000-720,126,000-823,605,000-327,300,000-165,287,000-135,697,000-83,993,000-215,940,000-220,779,000-218,664,000-175,149,000-142,939,000-124,472,000
Net Income Margin100.0%--0.23-0.30-0.36-0.51-0.40-0.34-0.45-0.48-0.48-0.56-0.26-0.16-0.13-0.10------
Free Cashflow100.0%--298,219,000-438,021,000-501,146,000-495,227,000-355,232,000-238,002,000-59,204,00087,888,00043,769,00071,404,000-89,426,000-237,704,000-261,158,000-283,457,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets0.8%6,3566,3046,2276,3076,4376,4916,6856,6546,7246,7354,9254,3544,4684,4613,5061,7591,7821,7711,5241,5101,483
  Current Assets7.6%1,1741,0919821,0491,1021,2151,4261,6161,6691,7752,1991,6071,5051,4845541,3201,3751,4071,2281,2901,310
    Cash Equivalents43.4%6044212422352131903162743641,1041,4918077047011781,034205285160162226
  Inventory5.4%13112411811511511310595.0090.0089.0092.0080.0082.0069.0062.0054.0048.0044.0039.0039.0035.00
  Net PPE---685--623580524502483452456463465455371335292245188140
  Goodwill0.0%2,3462,3462,3462,3452,3462,3352,3352,2432,24357.001,2381,2381,23830.001,203---15.00--
Liabilities1.6%3,2993,2473,1843,1983,2283,2323,2973,1973,1653,0862,6902,0171,9571,9231,2181,0111,016994843793738
  Current Liabilities32.9%48836741342444348151771067662963325322224423648149216813610783.00
    LT Debt, Current---------------1.00--0.000.00-5.00
    LT Debt, Non Current---------------24.00--25.0024.0017.001.00
Shareholder's Equity0.0%3,0573,0583,0433,1093,2093,2583,3883,4583,5593,6492,2361,7311,8871,8961,958748766777447717744
  Retained Earnings-2.4%-3,420-3,339-3,265-3,137-2,988-2,822-2,641-2,420-2,253-2,077-2,045-1,531-1,311-1,225-1,119-1,197-1,157-1,118-1,035-981-936
  Additional Paid-In Capital1.2%6,4766,3976,3126,2556,2056,0866,0295,8775,8115,7244,2793,8663,8203,7633,4061,9451,9201,8941,7171,6991,681
Shares Outstanding0.4%181180178177176174174172171169159150150148148128128126122123122
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations183.3%73.00-88.02-223-300-300-198-10234.00156109136-0.22-111-87.33-111-87.20-62.11-104-68.94-68.85-70.25
  Share Based Compensation1.4%20620420721717211425312516220115315914212210876.0069.0064.0060.0057.0051.00
Cashflow From Investing40.2%15611174.0021196.00-719-1,082-1,467-1,401-613-702-1,233-392-489-124704-232-260-782-747-795
Cashflow From Financing-22.8%16020776.0054.0054.004.008.009019059071,8801,0061,003993253256274502934928911

EXAS Income Statement

2023-06-30
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Revenue$ 622,093$ 521,640$ 1,224,543$ 1,008,211
Operating expenses    
Cost of sales (exclusive of amortization of acquired intangible assets)156,991144,600313,857279,305
Research and development104,095106,083199,514208,331
Sales and marketing176,490215,922363,454448,103
General and administrative237,965181,672455,260351,442
Amortization of acquired intangible assets22,92926,35645,85751,010
Impairment of long-lived assets5526,5916216,591
Total operating expenses699,022681,2241,378,5631,344,782
Loss from operations(76,929)(159,584)(154,020)(336,571)
Other income (expense)    
Investment income (loss), net4,828(3,719)5,318(5,206)
Interest expense(7,818)(4,511)(3,711)(8,989)
Total other income (expense)(2,990)(8,230)1,607(14,195)
Net loss before tax(79,919)(167,814)(152,413)(350,766)
Income tax benefit (expense)(1,107)1,751(2,764)3,766
Net loss$ (81,026)$ (166,063)$ (155,177)$ (347,000)
Net loss per share—basic (in usd per share)$ (0.45)$ (0.94)$ (0.87)$ (1.98)
Net loss per share—diluted (in usd per share)$ (0.45)$ (0.94)$ (0.87)$ (1.98)
Weighted average common shares outstanding—basic (in shares)180,204176,364179,393175,396
Weighted average common shares outstanding—diluted (in shares)180,204176,364179,393175,396

EXAS Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 604,363$ 242,493
Marketable securities171,349389,564
Accounts receivable, net178,317158,043
Inventory130,770118,259
Prepaid expenses and other current assets89,12973,898
Total current assets1,173,928982,257
Long-term Assets:  
Property, plant and equipment, net686,602684,756
Operating lease right-of-use assets148,690167,003
Goodwill2,346,2482,346,040
Intangible assets, net1,910,5591,956,240
Other long-term assets, net89,53690,577
Total assets6,355,5636,226,873
Current liabilities:  
Accounts payable75,08074,916
Accrued liabilities299,586299,216
Operating lease liabilities, current portion29,87228,366
Loans Payable, Current50,0000
Other current liabilities33,51910,249
Total current liabilities488,057412,747
Long-term liabilities:  
Convertible notes, net2,311,5672,186,106
Long-term debt, less current portion050,000
Other long-term liabilities330,816352,459
Operating lease liabilities, less current portion168,501182,399
Total liabilities3,298,9413,183,711
Commitments and contingencies (Note 14)
Stockholders’ equity:  
Preferred stock, $0.01 par value Authorized—5,000,000; shares issued and outstanding—no shares at June 30, 2023 and December 31, 202200
Common stock, $0.01 par value Authorized—400,000,000; shares issued and outstanding—180,545,663 and 177,925,631 shares at June 30, 2023 and December 31, 20221,8061,780
Additional paid-in capital6,475,7426,311,644
Accumulated other comprehensive loss(723)(5,236)
Accumulated deficit(3,420,203)(3,265,026)
Total stockholders’ equity3,056,6223,043,162
Total liabilities and stockholders’ equity$ 6,355,563$ 6,226,873
Kevin T. Conroy
6500
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.